$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
舒尼替尼治疗肺癌安全耐受
2025-10-19 11:44:20
Check Details
阿法替尼延长EGFR敏感突变肺癌患者无进展生存时间
2025-10-19 11:44:20
Check Details
阿法替尼治疗晚期肺鳞癌
2025-10-19 11:44:20
Check Details
舒尼替尼与化疗联合治疗NSCLC患者安全耐受
2025-10-19 11:44:20
Check Details
易瑞沙可用于晚期化疗失败的肺癌患者
2025-10-19 11:44:20
Check Details
特罗凯治疗肺鳞癌效果优于化疗
2025-10-19 11:44:20
Check Details
色瑞替尼治疗ALK阳性NSCLC疗效优于化疗
2025-10-19 11:44:20
Check Details
肺癌患者服用舒尼替尼常见的不良反应
2025-10-19 11:44:20
Check Details
克唑替尼使ROS1阳性NSCLC获益
2025-10-19 11:44:20
Check Details
奥希替尼治疗EGFR突变阳性的NSCLC有效率高达80%
2025-10-19 11:44:20
Check Details
艾乐替尼治疗亚洲肺癌患者疗效显著
2025-10-19 11:44:20
Check Details
克唑替尼获批我国ALK阳性NSCLC患者的治疗
2025-10-19 11:44:20
Check Details
1
2
...
2990
2991
2992
2993
2994
2995
2996
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
2
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
3
Vemurafenib (Zelboraf) Complete Medication Guide
4
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
5
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
6
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
7
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
8
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
9
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
10
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
11
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
12
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity